Am J Clin Oncol
-
Pretreatment Characteristics of Carcinoid Tumors of the Lung Which Predict
Aggressive Behavior: Erratum.
Am J Clin Oncol. 2024;47:e1.
- LIU X, Shen Q, Wen Y, Jiang Z, et al
Diagnosis of Malignant Pulmonary Nodules Using a Combination of Tumor-associated
Autoantibodies and Computed Tomography.
Am J Clin Oncol. 2024;47:149-154.
Ann Surg Oncol
- YAN HJ, Zhao JS, Zuo HD, Zhang JJ, et al
Dual-Region Computed Tomography Radiomics-Based Machine Learning Predicts
Subcarinal Lymph Node Metastasis in Patients with Non-small Cell Lung Cancer.
Ann Surg Oncol. 2024 Mar 23. doi: 10.1245/s10434-024-15197.
- LIU J, Shi Z, Cao B, Wang Z, et al
Prognostic Significance of the Highest Mediastinal Lymph Node Involvement in
Patients with Stage III-N2 Non-small Cell Lung Cancer.
Ann Surg Oncol. 2024 Mar 23. doi: 10.1245/s10434-024-15184.
Ann Thorac Surg
- BLASBERG JD, Li A
Evening the Odds: Making 1 + 1 = 2 for Bilobectomy.
Ann Thorac Surg. 2024;117:874-875.
- KAMIGAICHI A, Mimae T, Tsubokawa N, Miyata Y, et al
Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated
Lung Adenocarcinoma.
Ann Thorac Surg. 2024;117:743-751.
Anticancer Res
- MAEZAWA Y, Taguchi M, Kawakami T, Inui T, et al
Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter
Retrospective Study.
Anticancer Res. 2024;44:1751-1757.
- CHIU KL, Wang SC, Li CH, Shen TC, et al
The Contribution of Double-strand Break Repair Radiation Sensitive Protein 51
Genotypes to Lung Cancer in Taiwan.
Anticancer Res. 2024;44:1409-1416.
- HASHIMOTO K, Kaira K, Imai H, Miura YU, et al
Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1
Blocker in Extensive Stage Small Cell Lung Cancer.
Anticancer Res. 2024;44:1541-1551.
Arch Pathol Lab Med
- MILLER LJ, Holmes IM, Lew M
An Updated Contextual Approach to Mesothelial Proliferations in Pleural Effusion
Cytology Leveraging Morphology, Ancillary Studies, and Novel Biomarkers.
Arch Pathol Lab Med. 2024;148:409-418.
BMC Cancer
- QI H, Hou Y, Zheng Z, Zheng M, et al
Clinical characteristics and MRI based radiomics nomograms can predict iPFS and
short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung
adenocarcinoma with brain metastases.
BMC Cancer. 2024;24:362.
- LI LX, Socinski MA, Kichenadasse G, Karapetis CS, et al
A lack of association between BMI and chemoimmunotherapy efficacy in advanced
non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130
clinical trials.
BMC Cancer. 2024;24:379.
- XIE M, Gao J, Ma X, Song J, et al
The radiological characteristics, tertiary lymphoid structures, and survival
status associated with EGFR mutation in patients with subsolid nodules like stage
I-II LUAD.
BMC Cancer. 2024;24:372.
- ELBASHEER MMA, Bohrmann B, Chen Y, Lv J, et al
Reproductive factors and risk of lung cancer among 300,000 Chinese female
never-smokers: evidence from the China Kadoorie Biobank study.
BMC Cancer. 2024;24:384.
- WEI Q, Deng T, Wu J, Zeng H, et al
Immune checkpoint inhibitor plus chemotherapy as first-line treatment for
non-small cell lung cancer with malignant pleural effusion: a retrospective
multicenter study.
BMC Cancer. 2024;24:393.
Br J Cancer
- HARATANI K, Nakamura A, Mamesaya N, Sawa K, et al
Association of immune-related adverse events with durvalumab efficacy after
chemoradiotherapy in patients with unresectable Stage III non-small cell lung
cancer.
Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02662.
Cancer
- VITA E, Monaca F, Milardi D, Mastrantoni L, et al
Symptomatic androgen deficiency and sexual dysfunctions in male patients
receiving alectinib for ALK-positive advanced nonsmall cell lung cancer.
Cancer. 2024 Mar 28. doi: 10.1002/cncr.35293.
Cancer Chemother Pharmacol
- HUO H, Feng Y, Tang Q
Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the
malignant progression of lung cancer cells and increased the sensitivity to
chemotherapy.
Cancer Chemother Pharmacol. 2024 Mar 26. doi: 10.1007/s00280-024-04646.
Cancer Lett
- MORIMOTO K, Yamada T, Hirai S, Katayama Y, et al
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS
G12C-mutant tumor cells.
Cancer Lett. 2024;587:216692.
Clin Exp Metastasis
- HAIDER MT, Freytag V, Krause L, Spethmann T, et al
Comparison of ex vivo bioluminescence imaging, Alu-qPCR and histology for the
quantification of spontaneous lung and bone metastases in subcutaneous xenograft
mouse models.
Clin Exp Metastasis. 2024;41:103-115.
- POURJAMAL N, Yazdi N, Halme A, Joncour VL, et al
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab
vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
Clin Exp Metastasis. 2024 Feb 17. doi: 10.1007/s10585-024-10278.
Clin Lung Cancer
- NOURMOHAMMADI N, Liang THP, Sadigh G
Patient-Provider Lung Cancer Screening Discussions: An Analysis of a National
Survey.
Clin Lung Cancer. 2024 Mar 2:S1525-7304(24)00034.
Eur J Cardiothorac Surg
- WANG S, Bao X, Yang F, Shi H, et al
Multiparametric evaluation of mediastinal lymph node metastases in clinical
T0-T1c stage non-small-cell lung cancers.
Eur J Cardiothorac Surg. 2024;65:ezae059.
- MCALLISTER MA, Rochefort MM, Ugalde Figueroa P, Leo R, et al
Complete anatomic segmentectomy shows improved oncologic outcomes compared to
incomplete anatomic segmentectomy.
Eur J Cardiothorac Surg. 2024;65:ezae089.
- BACIEWICZ FA JR
'The Nodes Always Know'!
Eur J Cardiothorac Surg. 2024;65:ezae102.
- TIAN Y, Liu Z, Pan H, Zhu H, et al
Perioperative immune checkpoint blockades improve prognosis of resectable
non-small cell lung cancer.
Eur J Cardiothorac Surg. 2024 Mar 26:ezae110. doi: 10.1093.
Int J Radiat Oncol Biol Phys
- WALLS GM, Mistry H, Barlesi F, Bezjak A, et al
Long-term outcomes after concurrent once- or twice-daily chemoradiation in
limited-stage small-cell lung cancer: a brief report from the CONVERT trial.
Int J Radiat Oncol Biol Phys. 2024 Mar 11:S0360-3016(24)00382.
J Cancer Res Clin Oncol
- JIANG L, Yang P, Liu Y, Li J, et al
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case
report.
J Cancer Res Clin Oncol. 2024;150:162.
J Clin Oncol
- KATHURIA H, Wiener RS
Toward Racial Equity in Lung Cancer Screening Eligibility.
J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351.
- POTTER AL, Xu NN, Senthil P, Srinivasan D, et al
Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung
Cancer Screening Eligibility.
J Clin Oncol. 2024 Mar 27:JCO2301780. doi: 10.1200/JCO.23.01780.
J Comput Assist Tomogr
- MAGNINI A, Lorini C, Calistri L, Calcagni F, et al
The Impact of Rapid On-site Evaluation on Diagnostic Performance of Computed
Tomography-Guided Core Needle Biopsy in Lung Cancer.
J Comput Assist Tomogr. 2024 Mar 22. doi: 10.1097/RCT.0000000000001606.
JAMA Oncol
- ITO K, Suzuki Y, Sakaguchi T, Fujiwara K, et al
Physical Activity Using a Wearable Device as an Alternative to Performance Status
in Patients With Advanced Lung Cancer.
JAMA Oncol. 2024 Mar 28. doi: 10.1001/jamaoncol.2024.0023.
Lancet Oncol
- SMIT EF, Felip E, Uprety D, Nagasaka M, et al
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer
(DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a
single-arm, phase 2 trial.
Lancet Oncol. 2024;25:439-454.
Lung Cancer
- RODRIGUEZ J
On the Hispanic paradox in lung cancer.
Lung Cancer. 2024;190:107537.
- SUN M, Feng Q, Yan Q, Zhao H, et al
Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in
lung cancer.
Lung Cancer. 2024;190:107541.
Oncologist
- XU Y, Ji H, Zhang Y, Xiong L, et al
Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as
Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
Oncologist. 2024 Mar 25:oyae052. doi: 10.1093.
- PASELLO G, Lorenzi M, Scattolin D, Del Conte A, et al
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung
Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis
in Real-World.
Oncologist. 2024 Mar 23:oyae043. doi: 10.1093.
PLoS One
- LI Q, Wei Z, Zhang Y, Zheng C, et al
Causal role of metabolites in non-small cell lung cancer: Mendelian randomization
(MR) study.
PLoS One. 2024;19:e0300904.
- MOMOKI Y, Ichinose A, Nakamura K, Iwano S, et al
Development of automatic generation system for lung nodule finding descriptions.
PLoS One. 2024;19:e0300325.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016